GBIO Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of --. Generation Bio Co.'s return on equity of -84.94% beat CEL-SCI Corp.'s return on equity of -266.61%.

Generation Bio Co. has a consensus price target of $9.33, signalling upside risk potential of 78.8%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 575.68%. Given that CEL-SCI Corp. has higher upside potential than Generation Bio Co., analysts believe CEL-SCI Corp. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are larger than CEL-SCI Corp. quarterly revenues of --. Generation Bio Co.'s net income of -$5.5M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.45x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of -953.4%. Generation Bio Co.'s return on equity of -84.94% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Generation Bio Co. has a consensus price target of $9.33, signalling upside risk potential of 78.8%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1125.09%. Given that IGC Pharma, Inc. has higher upside potential than Generation Bio Co., analysts believe IGC Pharma, Inc. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Generation Bio Co.'s net income of -$5.5M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.45x versus 22.97x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of -255.85%. Generation Bio Co.'s return on equity of -84.94% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Generation Bio Co. has a consensus price target of $9.33, signalling upside risk potential of 78.8%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Generation Bio Co. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Generation Bio Co. is more attractive than NovaBay Pharmaceuticals, Inc..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Generation Bio Co. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Generation Bio Co.'s net income of -$5.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.45x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of 13.19%. Generation Bio Co.'s return on equity of -84.94% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Generation Bio Co. has a consensus price target of $9.33, signalling upside risk potential of 78.8%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 528.57%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Generation Bio Co., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Generation Bio Co.'s net income of -$5.5M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.45x versus 2.23x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.